Manufacturer of Controlled Substances; Notice of Application, 64744 [2010-26468]
Download as PDF
<![CDATA[
64744
Federal Register / Vol. 75, No. 202 / Wednesday, October 20, 2010 / Notices
the Correction to Notice of Application
pertaining to Rhodes Technologies, 72
FR 3417 (2007), comments and requests
for hearings on applications to import
narcotic raw material are not
appropriate.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 19, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic classes of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: October 8, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–26454 Filed 10–19–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
emcdonald on DSK2BSOYB1PROD with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
VerDate Mar<15>2010
17:17 Oct 19, 2010
Jkt 223001
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
September 15, 2010, Hospira Inc., 1776
North Centennial Drive, McPherson,
Kansas 67460–1247, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Remifentanil (9739), a
basic class of controlled substance listed
in schedule II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 22, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: October 8, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–26445 Filed 10–19–10; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 20, 2010,
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedule I:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Schedule
I
I
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol. In reference to
drug code 7370
(Tetrahydrocannabinols), the company
will manufacture a synthetic THC. No
other activity for this drug code is
authorized for registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 20, 2010.
Dated: October 8, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–26468 Filed 10–19–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 14,
2010, GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
E:\FR\FM\20OCN1.SGM
20OCN1
]]>Agencies
[Federal Register Volume 75, Number 202 (Wednesday, October 20, 2010)]
[Notices]
[Page 64744]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26468]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on August 20, 2010, Cayman
Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,
made application by renewal to the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the basic classes of controlled
substances listed in schedule I:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
------------------------------------------------------------------------
The company plans to manufacture small quantities of marihuana
derivatives for research purposes. In reference to drug code 7360
(Marihuana), the company plans to bulk manufacture cannabidiol. In
reference to drug code 7370 (Tetrahydrocannabinols), the company will
manufacture a synthetic THC. No other activity for this drug code is
authorized for registration.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 20, 2010.
Dated: October 8, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-26468 Filed 10-19-10; 8:45 am]
BILLING CODE 4410-09-P
